{"pageProps": {"talksPageBanner": {"banner": {"title": "TP WorkLife 10/12", "slug": "tp-worklife-10-12", "bannerLocation": "talks", "displayToExistingMembers": true, "mainContentHeadline": "The podcast where science meets business", "mainContent": "From fixing meetings to finding a mentor, get new insights to help you enjoy your time at work and thrive in your career.", "buttonLabel": "Listen now", "buttonLink": "https://www.ted.com/podcasts/fixable?utm_medium=website&utm_source=talkpage&utm_campaign=podcasts&utm_content=04112023-fixabletp", "showButtonIcon": false, "backgroundColor": "#FFEFA1", "textColor": "#000000", "useBackgroundGradient": false, "imageMobileBreakpoint": {"metadata": {"tags": []}, "sys": {"space": {"sys": {"type": "Link", "linkType": "Space", "id": "ab732rbh901q"}}, "id": "4BM5OASbSYegLKRYSri2gZ", "type": "Asset", "createdAt": "2023-10-11T21:22:04.069Z", "updatedAt": "2023-10-11T21:22:04.069Z", "environment": {"sys": {"id": "master", "type": "Link", "linkType": "Environment"}}, "revision": 1, "locale": "en-US"}, "fields": {"title": "WorkLife S6 - 659 x 1052x", "description": "", "file": {"url": "//images.ctfassets.net/ab732rbh901q/4BM5OASbSYegLKRYSri2gZ/c0a7605eca821fae7eea6c0359347d83/WorkLife_S6_-_659_x_1052x.png", "details": {"size": 29801, "image": {"width": 1318, "height": 210}}, "fileName": "WorkLife S6 - 659 x 1052x.png", "contentType": "image/png"}}}, "imageTabletBreakpoint": {"metadata": {"tags": []}, "sys": {"space": {"sys": {"type": "Link", "linkType": "Space", "id": "ab732rbh901q"}}, "id": "5DcAOXZmqMRBDk1Tb4tn87", "type": "Asset", "createdAt": "2023-10-11T21:25:23.492Z", "updatedAt": "2023-10-11T21:25:23.492Z", "environment": {"sys": {"id": "master", "type": "Link", "linkType": "Environment"}}, "revision": 1, "locale": "en-US"}, "fields": {"title": "WorkLife S6 - 1019 x 1602x (1)", "description": "", "file": {"url": "//images.ctfassets.net/ab732rbh901q/5DcAOXZmqMRBDk1Tb4tn87/11640e45662ad7292d8eb536a0de3f1e/WorkLife_S6_-_1019_x_1602x__1_.png", "details": {"size": 45372, "image": {"width": 2038, "height": 320}}, "fileName": "WorkLife S6 - 1019 x 1602x (1).png", "contentType": "image/png"}}}, "imageDesktopBreakpoint": {"metadata": {"tags": []}, "sys": {"space": {"sys": {"type": "Link", "linkType": "Space", "id": "ab732rbh901q"}}, "id": "3toTf7QHhGfKy59Qcx69dk", "type": "Asset", "createdAt": "2023-10-11T21:22:04.076Z", "updatedAt": "2023-10-11T21:22:04.076Z", "environment": {"sys": {"id": "master", "type": "Link", "linkType": "Environment"}}, "revision": 1, "locale": "en-US"}, "fields": {"title": "WorkLife S6 - 385 x 1052x", "description": "", "file": {"url": "//images.ctfassets.net/ab732rbh901q/3toTf7QHhGfKy59Qcx69dk/9b35ad517313f033f03f743e335118d5/WorkLife_S6_-_385_x_1052x.png", "details": {"size": 26833, "image": {"width": 770, "height": 210}}, "fileName": "WorkLife S6 - 385 x 1052x.png", "contentType": "image/png"}}}, "imageXLBreakpoint": {"metadata": {"tags": []}, "sys": {"space": {"sys": {"type": "Link", "linkType": "Space", "id": "ab732rbh901q"}}, "id": "3M4ANHhDr3Nwsd385dCSFK", "type": "Asset", "createdAt": "2023-10-11T21:22:04.078Z", "updatedAt": "2023-10-11T21:22:04.078Z", "environment": {"sys": {"id": "master", "type": "Link", "linkType": "Environment"}}, "revision": 1, "locale": "en-US"}, "fields": {"title": "WorkLife S6 - 472 x 1072x", "description": "", "file": {"url": "//images.ctfassets.net/ab732rbh901q/3M4ANHhDr3Nwsd385dCSFK/9d558d98ba8cbc09bb163323934ccd10/WorkLife_S6_-_472_x_1072x.png", "details": {"size": 27426, "image": {"width": 944, "height": 202}}, "fileName": "WorkLife S6 - 472 x 1072x.png", "contentType": "image/png"}}}}, "status": "published"}, "preview": false, "shortenedUrl": "https://go.ted.com/6WMa", "action": null, "videoData": {"__typename": "Video", "id": "46528", "slug": "carl_june_a_living_drug_that_could_change_the_way_we_treat_cancer", "title": "A \"living drug\" that could change the way we treat cancer", "socialTitle": "A \"living drug\" that could change the way we treat cancer", "presenterDisplayName": "Carl June", "internalLanguageCode": "en", "commentsEnabled": false, "commentsLoggedInOnly": false, "recordedOn": "2018-11-15", "curatorApproved": true, "viewedCount": 1983194, "duration": 900, "publishedAt": "2019-09-10T14:53:50Z", "topics": {"__typename": "TopicConnection", "nodes": [{"__typename": "Topic", "id": "8", "name": "science", "slug": "science"}, {"__typename": "Topic", "id": "53", "name": "innovation", "slug": "innovation"}, {"__typename": "Topic", "id": "57", "name": "disease", "slug": "disease"}, {"__typename": "Topic", "id": "59", "name": "health", "slug": "health"}, {"__typename": "Topic", "id": "66", "name": "cancer", "slug": "cancer"}, {"__typename": "Topic", "id": "129", "name": "medicine", "slug": "medicine"}, {"__typename": "Topic", "id": "199", "name": "humanity", "slug": "humanity"}, {"__typename": "Topic", "id": "596", "name": "human body", "slug": "human+body"}]}, "talkExtras": {"__typename": "TalkExtras", "recommendations": [], "takeAction": [], "learnModules": []}, "primaryImageSet": [{"__typename": "PhotoSize", "url": "https://talkstar-photos.s3.amazonaws.com/uploads/b9970160-1888-4717-9456-9c592413402d/CarlJune_2018P-embed.jpg", "aspectRatioName": "16x9"}, {"__typename": "PhotoSize", "url": "https://talkstar-photos.s3.amazonaws.com/uploads/8af49c28-122c-4d28-9605-1f31418f85a2/CarlJune_2018P-stageshot.jpg", "aspectRatioName": "4x3"}, {"__typename": "PhotoSize", "url": "https://talkstar-photos.s3.amazonaws.com/uploads/fdcdff52-3afb-45ea-8e0e-aefccb9ba854/CarlJune_2018P-1350x675.jpg", "aspectRatioName": "2x1"}], "relatedVideos": [{"__typename": "Video", "slug": "jimmy_lin_a_simple_new_blood_test_that_can_catch_cancer_early", "id": "2821"}, {"__typename": "Video", "slug": "hasini_jayatilaka_how_cancer_cells_communicate_and_how_we_can_slow_them_down", "id": "20919"}, {"__typename": "Video", "slug": "pedro_brugarolas_why_do_hospitals_have_particle_accelerators", "id": "36215"}, {"__typename": "Video", "slug": "elizabeth_wayne_we_can_hack_our_immune_cells_to_fight_cancer", "id": "3231"}, {"__typename": "Video", "slug": "carolyn_bertozzi_what_the_sugar_coating_on_your_cells_is_trying_to_tell_you", "id": "2850"}, {"__typename": "Video", "slug": "emma_bryce_what_is_hpv_and_how_can_you_protect_yourself_from_it", "id": "45086"}], "customContentDetails": {"__typename": "CustomContentDetails", "partnerName": null}, "speakers": {"__typename": "AcmeSpeakerConnection", "nodes": [{"__typename": "AcmeSpeaker", "photoUrl": "https://pe.tedcdn.com/images/ted/69767853202d833086949bb8944d5dd5aef59723_254x191.jpg", "firstname": "Carl", "middlename": "", "lastname": "June", "description": "Oncologist, researcher, professor", "isLive": true, "title": "", "whatOthersSay": "", "whoTheyAre": "Carl June is a renowned pioneer in the fight against cancer.", "whyListen": "<p>Carl June&#39;s revolutionary leukemia therapy, which was recently approved by the FDA, uses genetically engineered versions of a patient&rsquo;s own T cells and is the first personalized cell therapy for cancer to be sanctioned in America. Developed by June and his colleagues, this method has the potential to help patients with many other types of cancers.</p><p>June is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. A graduate of the Naval Academy in Annapolis and Baylor College of Medicine, he has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, as well as being named one of <em>TIME</em> Magazine&#39;s 100 Most Influential People in 2018.</p>", "slug": "carl_june"}]}, "description": "Carl June is the pioneer behind CAR T-cell therapy: a groundbreaking cancer treatment that supercharges part of a patient's own immune system to attack and kill tumors. In a talk about a breakthrough, he shares how three decades of research culminated in a therapy that's eradicated cases of leukemia once thought to be incurable -- and explains how it could be used to fight other types of cancer.", "socialDescription": "Carl June is the pioneer behind CAR T-cell therapy: a groundbreaking cancer treatment that supercharges part of a patient's own immune system to attack and kill tumors. In a talk about a breakthrough, he shares how three decades of research culminated in a therapy that's eradicated cases of leukemia once thought to be incurable -- and explains how it could be used to fight other types of cancer.", "partnerName": null, "playerData": "{\"id\":\"46528\",\"mediaIdentifier\":\"consus-pm582-im2346\",\"mediaProjectVersionIdentifier\":\"consus-pm582-im2346\",\"duration\":909,\"languages\":[{\"languageName\":\"English\",\"endonym\":\"English\",\"languageCode\":\"en\",\"ianaCode\":\"en\",\"isRtl\":false},{\"languageName\":\"Portuguese, Brazilian\",\"endonym\":\"Portugu\u00eas brasileiro\",\"languageCode\":\"pt-br\",\"ianaCode\":\"pt-BR\",\"isRtl\":false},{\"languageName\":\"Persian\",\"endonym\":\"\u0641\u0627\u0631\u0633\u0649\",\"languageCode\":\"fa\",\"ianaCode\":\"fa\",\"isRtl\":true},{\"languageName\":\"Romanian\",\"endonym\":\"Rom\u00e2n\u0103\",\"languageCode\":\"ro\",\"ianaCode\":\"ro\",\"isRtl\":false},{\"languageName\":\"Korean\",\"endonym\":\"\ud55c\uad6d\uc5b4\",\"languageCode\":\"ko\",\"ianaCode\":\"ko\",\"isRtl\":false},{\"languageName\":\"Turkish\",\"endonym\":\"T\u00fcrk\u00e7e\",\"languageCode\":\"tr\",\"ianaCode\":\"tr\",\"isRtl\":false},{\"languageName\":\"Indonesian\",\"endonym\":\"Bahasa Indonesia\",\"languageCode\":\"id\",\"ianaCode\":\"id\",\"isRtl\":false},{\"languageName\":\"Spanish\",\"endonym\":\"Espa\u00f1ol\",\"languageCode\":\"es\",\"ianaCode\":\"es\",\"isRtl\":false},{\"languageName\":\"Gujarati\",\"endonym\":\"\u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0\",\"languageCode\":\"gu\",\"ianaCode\":\"gu\",\"isRtl\":false},{\"languageName\":\"French\",\"endonym\":\"Fran\u00e7ais\",\"languageCode\":\"fr\",\"ianaCode\":\"fr\",\"isRtl\":false},{\"languageName\":\"German\",\"endonym\":\"Deutsch\",\"languageCode\":\"de\",\"ianaCode\":\"de\",\"isRtl\":false},{\"languageName\":\"Chinese, Traditional\",\"endonym\":\"\u4e2d\u6587 (\u7e41\u9ad4)\",\"languageCode\":\"zh-tw\",\"ianaCode\":\"zh-Hant\",\"isRtl\":false},{\"languageName\":\"Russian\",\"endonym\":\"\u0420\u0443\u0441\u0441\u043a\u0438\u0439\",\"languageCode\":\"ru\",\"ianaCode\":\"ru\",\"isRtl\":false},{\"languageName\":\"Chinese, Simplified\",\"endonym\":\"\u4e2d\u6587 (\u7b80\u4f53)\",\"languageCode\":\"zh-cn\",\"ianaCode\":\"zh-Hans\",\"isRtl\":false},{\"languageName\":\"Japanese\",\"endonym\":\"\u65e5\u672c\u8a9e\",\"languageCode\":\"ja\",\"ianaCode\":\"ja\",\"isRtl\":false},{\"languageName\":\"Vietnamese\",\"endonym\":\"Ti\u1ebfng Vi\u1ec7t\",\"languageCode\":\"vi\",\"ianaCode\":\"vi\",\"isRtl\":false},{\"languageName\":\"Arabic\",\"endonym\":\"\u0627\u0644\u0639\u0631\u0628\u064a\u0629\",\"languageCode\":\"ar\",\"ianaCode\":\"ar\",\"isRtl\":true},{\"languageName\":\"Greek\",\"endonym\":\"\u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ac\",\"languageCode\":\"el\",\"ianaCode\":\"el\",\"isRtl\":false},{\"languageName\":\"Portuguese\",\"endonym\":\"Portugu\u00eas de Portugal\",\"languageCode\":\"pt\",\"ianaCode\":\"pt\",\"isRtl\":false}],\"nativeLanguage\":\"en\",\"isSubtitleRequired\":false,\"resources\":{\"h264\":[{\"bitrate\":1200,\"file\":\"https://py.tedcdn.com/consus/projects/00/05/82/003/products/2018p-carl-june-003-fallback-b2acd3687c44871a2d565d6555c02f52-1200k.mp4\"}],\"hls\":{\"adUrl\":\"https://pubads.g.doubleclick.net/gampad/ads?ciu_szs=300x250%2C512x288%2C120x60%2C320x50%2C6x7%2C6x8&correlator=%5Bcorrelator%5D&cust_params=event%3DTEDMED%2B2018%26id%3D46528%26tag%3Dmedicine%2Ccancer%2Cdisease%2Chealth%2Chuman%2Bbody%2Cinnovation%2Chumanity%2Cscience%26talk%3Dcarl_june_a_living_drug_that_could_change_the_way_we_treat_cancer%26year%3D2018&env=vp&gdfp_req=1&impl=s&iu=%2F5641%2Fmobile%2Fios%2Fweb&output=xml_vast2&sz=640x360&unviewed_position_start=1&url=%5Breferrer%5D\",\"maiTargeting\":{\"id\":\"46528\",\"talk\":\"carl_june_a_living_drug_that_could_change_the_way_we_treat_cancer\",\"tag\":\"medicine,cancer,disease,health,human body,innovation,humanity,science\",\"year\":\"2018\",\"event\":\"TEDMED 2018\"},\"stream\":\"https://hls.ted.com/project_masters/582/manifest.m3u8?intro_master_id=2346\",\"metadata\":\"https://hls.ted.com/project_masters/582/metadata.json?intro_master_id=2346\"}},\"targeting\":{\"id\":\"46528\",\"talk\":\"carl_june_a_living_drug_that_could_change_the_way_we_treat_cancer\",\"tag\":\"medicine,cancer,disease,health,human body,innovation,humanity,science\",\"year\":\"2018\",\"event\":\"TEDMED 2018\"},\"canonical\":\"https://www.ted.com/talks/carl_june_a_living_drug_that_could_change_the_way_we_treat_cancer\",\"name\":\"Carl June: A \\\"living drug\\\" that could change the way we treat cancer\",\"title\":\"A \\\"living drug\\\" that could change the way we treat cancer\",\"speaker\":\"Carl June\",\"thumb\":\"https://pi.tedcdn.com/r/talkstar-photos.s3.amazonaws.com/uploads/b9970160-1888-4717-9456-9c592413402d/CarlJune_2018P-embed.jpg?quality=89&w=600\",\"slug\":\"carl_june_a_living_drug_that_could_change_the_way_we_treat_cancer\",\"event\":\"TEDMED 2018\",\"published\":1568127230,\"external\":{\"service\":\"YouTube\",\"code\":\"7qWvVcBZzRg\",\"duration\":910.0,\"start_time\":0.0}}", "videoContext": "TEDMED 2018", "audioInternalLanguageCode": "en", "language": "en", "hasTranslations": true, "featured": true, "type": {"__typename": "TypeOfVideo", "id": "1", "name": "TED Stage Talk"}}, "transcriptData": {"translation": {"__typename": "Translation", "id": "162109", "language": {"__typename": "Language", "id": "35", "endonym": "English", "englishName": "English", "internalLanguageCode": "en", "rtl": false}, "reviewer": null, "translator": null, "paragraphs": [{"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So this is the first time\nI've told this story in public,", "time": 952}, {"__typename": "Cue", "text": "the personal aspects of it.", "time": 3882}, {"__typename": "Cue", "text": "Yogi Berra was a world-famous\nbaseball player who said,", "time": 7056}, {"__typename": "Cue", "text": "\"If you come to a fork\nin the road, take it.\"", "time": 12157}, {"__typename": "Cue", "text": "Researchers had been,\nfor more than a century,", "time": 15069}, {"__typename": "Cue", "text": "studying the immune system\nas a way to fight cancer,", "time": 18592}, {"__typename": "Cue", "text": "and cancer vaccines have,\nunfortunately, been disappointing.", "time": 22482}, {"__typename": "Cue", "text": "They've only worked in cancers\ncaused by viruses,", "time": 25966}, {"__typename": "Cue", "text": "like cervical cancer or liver cancer.", "time": 28800}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So cancer researchers basically\ngave up on the idea", "time": 33129}, {"__typename": "Cue", "text": "of using the immune system\nto fight cancer.", "time": 35963}, {"__typename": "Cue", "text": "And the immune system, in any case,\ndid not evolve to fight cancer;", "time": 40127}, {"__typename": "Cue", "text": "it evolved to fight pathogens\ninvading from the outside.", "time": 44147}, {"__typename": "Cue", "text": "So its job is to kill\nbacteria and viruses.", "time": 47962}, {"__typename": "Cue", "text": "And the reason the immune system\nhas trouble with most cancers", "time": 51479}, {"__typename": "Cue", "text": "is that it doesn't invade\nfrom the outside;", "time": 54847}, {"__typename": "Cue", "text": "it evolves from its own cells.", "time": 58315}, {"__typename": "Cue", "text": "And so either the immune system does\nnot recognize the cancer as a problem,", "time": 62337}, {"__typename": "Cue", "text": "or it attacks a cancer\nand also our normal cells,", "time": 66568}, {"__typename": "Cue", "text": "leading to autoimmune diseases\nlike colitis or multiple sclerosis.", "time": 69877}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So how do you get around that?", "time": 74991}, {"__typename": "Cue", "text": "Our answer turned out to be\nsynthetic immune systems", "time": 76814}, {"__typename": "Cue", "text": "that are designed to recognize\nand kill cancer cells.", "time": 81672}, {"__typename": "Cue", "text": "That's right -- I said\na synthetic immune system.", "time": 85609}, {"__typename": "Cue", "text": "You do that with genetic engineering\nand synthetic biology.", "time": 90978}, {"__typename": "Cue", "text": "We did it with the naturally occurring\nparts of the immune system,", "time": 95780}, {"__typename": "Cue", "text": "called B cells and T cells.", "time": 98956}, {"__typename": "Cue", "text": "These were our building blocks.", "time": 100910}, {"__typename": "Cue", "text": "T cells have evolved to kill\ncells infected with viruses,", "time": 103522}, {"__typename": "Cue", "text": "and B cells are the cells that make\nantibodies that are secreted", "time": 107220}, {"__typename": "Cue", "text": "and then bind to kill bacteria.", "time": 111383}, {"__typename": "Cue", "text": "Well, what if you combined\nthese two functions", "time": 115012}, {"__typename": "Cue", "text": "in a way that was designed\nto repurpose them to fight cancer?", "time": 119379}, {"__typename": "Cue", "text": "We realized it would be possible\nto insert the genes for antibodies", "time": 123474}, {"__typename": "Cue", "text": "from B cells into T cells.", "time": 127125}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So how do you do that?", "time": 129854}, {"__typename": "Cue", "text": "Well, we used an HIV virus\nas a Trojan horse", "time": 132109}, {"__typename": "Cue", "text": "to get past the T cells' immune system.", "time": 136179}, {"__typename": "Cue", "text": "The result is a chimera,", "time": 140464}, {"__typename": "Cue", "text": "a fantastic fire-breathing creature\nfrom Greek mythology,", "time": 142075}, {"__typename": "Cue", "text": "with a lion's head, a goat's body\nand a serpent's tail.", "time": 146212}, {"__typename": "Cue", "text": "So we decided that the paradoxical\nthing that we had created", "time": 150720}, {"__typename": "Cue", "text": "with our B-cell antibodies,\nour T cells carrier", "time": 154403}, {"__typename": "Cue", "text": "and the HIV Trojan horse", "time": 158620}, {"__typename": "Cue", "text": "should be called \"Chimeric Antigen\nReceptor T cells,\" or CAR T cells.", "time": 160712}, {"__typename": "Cue", "text": "The virus also inserts genetic information", "time": 166538}, {"__typename": "Cue", "text": "to activate the T cells and program them\ninto their killing mode.", "time": 169545}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So when CAR T cells are injected\ninto somebody with cancer,", "time": 173915}, {"__typename": "Cue", "text": "what happens when those CAR T cells\nsee and bind to their tumor target?", "time": 178018}, {"__typename": "Cue", "text": "They act like supercharged killer\nT cells on steroids.", "time": 182688}, {"__typename": "Cue", "text": "They start this crash-defense\nbuildup system in the body", "time": 187197}, {"__typename": "Cue", "text": "and literally divide\nand multiply by the millions,", "time": 190617}, {"__typename": "Cue", "text": "where they then attack and kill the tumor.", "time": 193701}, {"__typename": "Cue", "text": "All of this means that CAR T cells\nare the first living drug in medicine.", "time": 196550}, {"__typename": "Cue", "text": "CAR T cells break the mold.", "time": 202375}, {"__typename": "Cue", "text": "Unlike normal drugs that you take --", "time": 203863}, {"__typename": "Cue", "text": "they do their job and get metabolized,\nand then you have to take them again --", "time": 206141}, {"__typename": "Cue", "text": "CAR T cells stay alive\nand on the job for years.", "time": 210339}, {"__typename": "Cue", "text": "We have had CAR T cells stay\nin the bodies of our cancer patients", "time": 214530}, {"__typename": "Cue", "text": "now for more than eight years.", "time": 219113}, {"__typename": "Cue", "text": "And these designer\ncancer T cells, CAR T cells,", "time": 222196}, {"__typename": "Cue", "text": "have a calculated half-life\nof more than 17 years.", "time": 225458}, {"__typename": "Cue", "text": "So one infusion can do the job;", "time": 229450}, {"__typename": "Cue", "text": "they stay on patrol\nfor the rest of your life.", "time": 231422}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "This is the beginning\nof a new paradigm in medicine.", "time": 234403}, {"__typename": "Cue", "text": "Now, there was one major challenge\nto these T-cell infusions.", "time": 238173}, {"__typename": "Cue", "text": "The only source of T cells\nthat will work in a patient", "time": 243903}, {"__typename": "Cue", "text": "are your own T cells,", "time": 248194}, {"__typename": "Cue", "text": "unless you happen to have\nan identical twin.", "time": 249385}, {"__typename": "Cue", "text": "So for most of us, we're out of luck.", "time": 252234}, {"__typename": "Cue", "text": "So what we did was to make CAR T cells.", "time": 256440}, {"__typename": "Cue", "text": "We had to learn to grow\nthe patient's own T cells.", "time": 260309}, {"__typename": "Cue", "text": "And we developed a robust\nplatform for this in the 1990s.", "time": 263381}, {"__typename": "Cue", "text": "Then in 1997, we first tested\nCAR T cells in patients", "time": 267831}, {"__typename": "Cue", "text": "with advanced HIV-AIDS.", "time": 271887}, {"__typename": "Cue", "text": "And we found that those CAR T cells\nsurvived in the patients", "time": 274268}, {"__typename": "Cue", "text": "for more than a decade.", "time": 277390}, {"__typename": "Cue", "text": "And it improved their immune system\nand decreased their viruses,", "time": 278998}, {"__typename": "Cue", "text": "but it didn't cure them.", "time": 282037}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So we went back to the laboratory,\nand over the next decade", "time": 283427}, {"__typename": "Cue", "text": "made improvements\nto the CAR T cell design.", "time": 286292}, {"__typename": "Cue", "text": "And by 2010, we began treating\nleukemia patients.", "time": 289173}, {"__typename": "Cue", "text": "And our team treated three patients", "time": 293663}, {"__typename": "Cue", "text": "with advanced chronic\nlymphocytic leukemia in 2012.", "time": 296044}, {"__typename": "Cue", "text": "It's a form of incurable leukemia", "time": 299806}, {"__typename": "Cue", "text": "that afflicts approximately 20,000 adults\nevery year in the United States.", "time": 302498}, {"__typename": "Cue", "text": "The first patient that we treated\nwas a retired Marine sergeant", "time": 307887}, {"__typename": "Cue", "text": "and a prison corrections officer.", "time": 312945}, {"__typename": "Cue", "text": "He had only weeks to live", "time": 314895}, {"__typename": "Cue", "text": "and had, in fact, already paid\nfor his funeral.", "time": 316228}, {"__typename": "Cue", "text": "The cells were infused,\nand within days, he had high fevers.", "time": 321450}, {"__typename": "Cue", "text": "He developed multiple organ failures,", "time": 325621}, {"__typename": "Cue", "text": "was transferred to the ICU\nand was comatose.", "time": 327422}, {"__typename": "Cue", "text": "We thought he would die,", "time": 329795}, {"__typename": "Cue", "text": "and, in fact, he was given last rites.", "time": 331383}, {"__typename": "Cue", "text": "But then, another\nfork in the road happened.", "time": 333859}, {"__typename": "Cue", "text": "So, around 28 days after\nthe CAR T cell infusion,", "time": 338722}, {"__typename": "Cue", "text": "he woke up,", "time": 341730}, {"__typename": "Cue", "text": "and the physicians finally examined him,", "time": 342911}, {"__typename": "Cue", "text": "and the cancer was gone.", "time": 345189}, {"__typename": "Cue", "text": "The big masses that\nhad been there had melted.", "time": 346481}, {"__typename": "Cue", "text": "Bone marrow biopsies found\nno evidence of leukemia,", "time": 349823}, {"__typename": "Cue", "text": "and that year, in our first\nthree patients we treated,", "time": 352244}, {"__typename": "Cue", "text": "two of three have had durable remissions\nnow for eight years,", "time": 355268}, {"__typename": "Cue", "text": "and one had a partial remission.", "time": 358548}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "The CAR T cells had attacked\nthe leukemia in these patients", "time": 361230}, {"__typename": "Cue", "text": "and had dissolved between 2.9\nand 7.7 pounds of tumor in each patient.", "time": 364554}, {"__typename": "Cue", "text": "Their bodies had become veritable\nbioreactors for these CAR T cells,", "time": 372649}, {"__typename": "Cue", "text": "producing millions\nand millions of CAR T cells", "time": 377506}, {"__typename": "Cue", "text": "in the bone marrow,\nblood and tumor masses.", "time": 380387}, {"__typename": "Cue", "text": "And we discovered that these CAR T cells\ncan punch far above their weight class,", "time": 384511}, {"__typename": "Cue", "text": "to use a boxing analogy.", "time": 388820}, {"__typename": "Cue", "text": "Just one CAR T cell can kill\n1,000 tumor cells.", "time": 390718}, {"__typename": "Cue", "text": "That's right -- it's a ratio\nof one to a thousand.", "time": 395697}, {"__typename": "Cue", "text": "The CAR T cell and\nits daughter progeny cells", "time": 398623}, {"__typename": "Cue", "text": "can divide and divide\nand divide in the body", "time": 401665}, {"__typename": "Cue", "text": "until the last tumor cell is gone.", "time": 404125}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "There's no precedent for this\nin cancer medicine.", "time": 406284}, {"__typename": "Cue", "text": "The first two patients\nwho had full remission", "time": 409379}, {"__typename": "Cue", "text": "remain today leukemia-free,", "time": 412583}, {"__typename": "Cue", "text": "and we think they are cured.", "time": 415683}, {"__typename": "Cue", "text": "These are people\nwho had run out of options,", "time": 417297}, {"__typename": "Cue", "text": "and by all traditional methods they had,", "time": 421106}, {"__typename": "Cue", "text": "they were like modern-day Lazarus cases.", "time": 423807}, {"__typename": "Cue", "text": "All I can say is: thank goodness\nfor those forks in the road.", "time": 426870}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "Our next step was to get permission\nto treat children with acute leukemia,", "time": 431196}, {"__typename": "Cue", "text": "the most common form of cancer in kids.", "time": 435730}, {"__typename": "Cue", "text": "The first patient we enrolled\non the trial was Emily Whitehead,", "time": 438419}, {"__typename": "Cue", "text": "and at that time, she was six years old.", "time": 441466}, {"__typename": "Cue", "text": "She had gone through\na series of chemotherapy", "time": 443538}, {"__typename": "Cue", "text": "and radiation treatments\nover several years,", "time": 446188}, {"__typename": "Cue", "text": "and her leukemia had always come back.", "time": 448752}, {"__typename": "Cue", "text": "In fact, it had come back three times.", "time": 450626}, {"__typename": "Cue", "text": "When we first saw her, Emily was very ill.", "time": 453276}, {"__typename": "Cue", "text": "Her official diagnosis\nwas advanced, incurable leukemia.", "time": 459244}, {"__typename": "Cue", "text": "Cancer had invaded her bone marrow,\nher liver, her spleen.", "time": 463822}, {"__typename": "Cue", "text": "And when we infused her\nwith the CAR T cells", "time": 468179}, {"__typename": "Cue", "text": "in the spring of April 2012,", "time": 471027}, {"__typename": "Cue", "text": "over the next few days,\nshe did not get better.", "time": 473693}, {"__typename": "Cue", "text": "She got worse, and in fact, much worse.", "time": 476550}, {"__typename": "Cue", "text": "As our prison corrections\nofficer had in 2010,", "time": 479367}, {"__typename": "Cue", "text": "she, in 2012, was admitted to the ICU,", "time": 482613}, {"__typename": "Cue", "text": "and this was the scariest fork\nin the whole road of this story.", "time": 485623}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "By day three, she was comatose\nand on life support", "time": 489559}, {"__typename": "Cue", "text": "for kidney failure, lung failure and coma.", "time": 494522}, {"__typename": "Cue", "text": "Her fever was as high\nas 106 degrees Fahrenheit for three days.", "time": 498263}, {"__typename": "Cue", "text": "And we didn't know\nwhat was causing those fevers.", "time": 503239}, {"__typename": "Cue", "text": "We did all the standard\nblood tests for infections,", "time": 506730}, {"__typename": "Cue", "text": "and we could not find\nan infectious cause for her fever.", "time": 509149}, {"__typename": "Cue", "text": "But we did find something\nvery unusual in her blood", "time": 512703}, {"__typename": "Cue", "text": "that had never been seen\nbefore in medicine.", "time": 516664}, {"__typename": "Cue", "text": "She had elevated levels of a protein\ncalled interleukin-6, or IL-6,", "time": 519374}, {"__typename": "Cue", "text": "in her blood.", "time": 524742}, {"__typename": "Cue", "text": "It was, in fact, more than a thousandfold\nabove the normal levels.", "time": 525934}, {"__typename": "Cue", "text": "And here's where yet another\nfork in the road came in.", "time": 531450}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "By sheer coincidence,", "time": 536548}, {"__typename": "Cue", "text": "one of my daughters has a form\nof pediatric arthritis.", "time": 538199}, {"__typename": "Cue", "text": "And as a result, I had been\nfollowing as a cancer doc,", "time": 544505}, {"__typename": "Cue", "text": "experimental therapies\nfor arthritis for my daughter,", "time": 547728}, {"__typename": "Cue", "text": "in case she would need them.", "time": 551553}, {"__typename": "Cue", "text": "And it so happened that just months\nbefore Emily was admitted to the hospital,", "time": 552950}, {"__typename": "Cue", "text": "a new therapy had been approved by the FDA", "time": 557197}, {"__typename": "Cue", "text": "to treat elevated levels of interleukin-6.", "time": 560137}, {"__typename": "Cue", "text": "And it was approved for the arthritis\nthat my daughter had.", "time": 562871}, {"__typename": "Cue", "text": "It's called tocilizumab.", "time": 565665}, {"__typename": "Cue", "text": "And, in fact, it had just been added\nto the pharmacy at Emily's hospital,", "time": 568584}, {"__typename": "Cue", "text": "for arthritis.", "time": 573742}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So when we found Emily had\nthese very high levels of IL-6,", "time": 575419}, {"__typename": "Cue", "text": "I called her doctors in the ICU and said,", "time": 578522}, {"__typename": "Cue", "text": "\"Why don't you treat her\nwith this arthritis drug?\"", "time": 581284}, {"__typename": "Cue", "text": "They said I was a cowboy\nfor suggesting that.", "time": 584700}, {"__typename": "Cue", "text": "And since her fever and low blood pressure", "time": 587517}, {"__typename": "Cue", "text": "had not responded to any other therapy,", "time": 589978}, {"__typename": "Cue", "text": "her doctor quickly asked permission\nto the institutional review board,", "time": 593292}, {"__typename": "Cue", "text": "her parents,", "time": 596626}, {"__typename": "Cue", "text": "and everybody, of course, said yes.", "time": 597807}, {"__typename": "Cue", "text": "And they tried it,", "time": 599641}, {"__typename": "Cue", "text": "and the results were nothing\nshort of striking.", "time": 600866}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "Within hours after treatment\nwith tocilizumab,", "time": 604701}, {"__typename": "Cue", "text": "Emily began to improve very rapidly.", "time": 607383}, {"__typename": "Cue", "text": "Twenty-three days after her treatment,", "time": 610764}, {"__typename": "Cue", "text": "she was declared cancer-free.", "time": 614122}, {"__typename": "Cue", "text": "And today, she's 12 years old\nand still in remission.", "time": 616220}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "(Applause)", "time": 622840}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So we now call this violent reaction\nof the high fevers and coma,", "time": 632707}, {"__typename": "Cue", "text": "following CAR T cells,", "time": 638557}, {"__typename": "Cue", "text": "cytokine release syndrome, or CRS.", "time": 639739}, {"__typename": "Cue", "text": "We've found that it occurs in nearly\nall patients who respond to the therapy.", "time": 642387}, {"__typename": "Cue", "text": "But it does not happen\nin those patients who fail to respond.", "time": 646276}, {"__typename": "Cue", "text": "So paradoxically,", "time": 649673}, {"__typename": "Cue", "text": "our patients now hope\nfor these high fevers after therapy,", "time": 652466}, {"__typename": "Cue", "text": "which feels like\n\"the worst flu in their life,\"", "time": 656950}, {"__typename": "Cue", "text": "when they get CAR T-cell therapies.", "time": 659776}, {"__typename": "Cue", "text": "They hope for this reaction", "time": 661570}, {"__typename": "Cue", "text": "because they know it's part\nof the twisting and turning path", "time": 662899}, {"__typename": "Cue", "text": "back to health.", "time": 666053}, {"__typename": "Cue", "text": "Unfortunately, not every patient recovers.", "time": 667403}, {"__typename": "Cue", "text": "Patients who do not get CRS\nare often those who are not cured.", "time": 670458}, {"__typename": "Cue", "text": "So there's a strong link now between CRS", "time": 675258}, {"__typename": "Cue", "text": "and the ability of the immune system\nto eradicate leukemia.", "time": 678457}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "That's why last summer,", "time": 681973}, {"__typename": "Cue", "text": "when the FDA approved\nCAR T cells for leukemia,", "time": 683156}, {"__typename": "Cue", "text": "they also co-approved the use\nof tocilizumab to block the IL-6 effects", "time": 689252}, {"__typename": "Cue", "text": "and the accompanying CRS\nin these patients.", "time": 695394}, {"__typename": "Cue", "text": "That was a very unusual event\nin medical history.", "time": 698711}, {"__typename": "Cue", "text": "Emily's doctors have now\ncompleted further trials", "time": 702784}, {"__typename": "Cue", "text": "and reported that 27 out of 30 patients,\nthe first 30 we treated,", "time": 707499}, {"__typename": "Cue", "text": "or 90 percent,", "time": 712131}, {"__typename": "Cue", "text": "had a complete remission", "time": 713311}, {"__typename": "Cue", "text": "after CAR T cells, within a month.", "time": 716175}, {"__typename": "Cue", "text": "A 90 percent complete remission rate\nin patients with advanced cancer", "time": 718830}, {"__typename": "Cue", "text": "is unheard of", "time": 723354}, {"__typename": "Cue", "text": "in more than 50 years of cancer research.", "time": 724534}, {"__typename": "Cue", "text": "In fact, companies often declare\nsuccess in a cancer trial", "time": 727431}, {"__typename": "Cue", "text": "if 15 percent of the patients\nhad a complete response rate.", "time": 732220}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "A remarkable study appeared in the\n\"New England Journal of Medicine\" in 2013.", "time": 736180}, {"__typename": "Cue", "text": "An international study\nhas since confirmed those results.", "time": 740673}, {"__typename": "Cue", "text": "And that led to the approval by the FDA", "time": 744442}, {"__typename": "Cue", "text": "for pediatric and young adult\nleukemia in August of 2017.", "time": 748038}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "So as a first-ever approval\nof a cell and gene therapy,", "time": 753275}, {"__typename": "Cue", "text": "CAR T-cell therapy\nhas also been tested now", "time": 756726}, {"__typename": "Cue", "text": "in adults with refractory lymphoma.", "time": 758966}, {"__typename": "Cue", "text": "This disease afflicts about 20,000\na year in the United States.", "time": 761885}, {"__typename": "Cue", "text": "The results were equally impressive\nand have been durable to date.", "time": 766004}, {"__typename": "Cue", "text": "And six months ago, the FDA approved\nthe therapy of this advanced lymphoma", "time": 770172}, {"__typename": "Cue", "text": "with CAR T cells.", "time": 775073}, {"__typename": "Cue", "text": "So now there are many labs and physicians\nand scientists around the world", "time": 776974}, {"__typename": "Cue", "text": "who have tested CAR T cells", "time": 782015}, {"__typename": "Cue", "text": "across many different diseases,", "time": 784136}, {"__typename": "Cue", "text": "and understandably, we're all thrilled\nwith the rapid pace of advancement.", "time": 786970}, {"__typename": "Cue", "text": "We're so grateful to see patients\nwho were formerly terminal", "time": 791431}, {"__typename": "Cue", "text": "return to healthy lives, as Emily has.", "time": 795058}, {"__typename": "Cue", "text": "We're thrilled to see long remissions\nthat may, in fact, be a cure.", "time": 798892}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "At the same time, we're also concerned\nabout the financial cost.", "time": 802363}, {"__typename": "Cue", "text": "It can cost up to 150,000 dollars\nto make the CAR T cells for each patient.", "time": 806196}, {"__typename": "Cue", "text": "And when you add in the cost\nof treating CRS and other complications,", "time": 811696}, {"__typename": "Cue", "text": "the cost can reach\none million dollars per patient.", "time": 815375}, {"__typename": "Cue", "text": "We must remember that the cost\nof failure, though, is even worse.", "time": 819343}, {"__typename": "Cue", "text": "The current noncurative therapies\nfor cancer are also expensive", "time": 823271}, {"__typename": "Cue", "text": "and, in addition, the patient dies.", "time": 826610}, {"__typename": "Cue", "text": "So, of course, we'd like to see\nresearch done now", "time": 829744}, {"__typename": "Cue", "text": "to make this more efficient", "time": 832544}, {"__typename": "Cue", "text": "and increase affordability\nto all patients.", "time": 836367}, {"__typename": "Cue", "text": "Fortunately, this is a new\nand evolving field,", "time": 839176}, {"__typename": "Cue", "text": "and as with many other new\ntherapies and services,", "time": 841431}, {"__typename": "Cue", "text": "prices will come down as industry learns\nto do things more efficiently.", "time": 844999}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "When I think about\nall the forks in the road", "time": 849737}, {"__typename": "Cue", "text": "that have led to CAR T-cell therapy,", "time": 851840}, {"__typename": "Cue", "text": "there is one thing that strikes me\nas very important.", "time": 853974}, {"__typename": "Cue", "text": "We're reminded that discoveries\nof this magnitude don't happen overnight.", "time": 857474}, {"__typename": "Cue", "text": "CAR T-cell therapies came to us\nafter a 30-year journey,", "time": 861426}, {"__typename": "Cue", "text": "along a road full of setbacks\nand surprises.", "time": 865776}, {"__typename": "Cue", "text": "In all this world of instant gratification", "time": 869093}, {"__typename": "Cue", "text": "and 24/7, on-demand results,", "time": 871529}, {"__typename": "Cue", "text": "scientists require persistence,\nvision and patience", "time": 874601}, {"__typename": "Cue", "text": "to rise above all that.", "time": 878753}, {"__typename": "Cue", "text": "They can see that the fork in the road\nis not always a dilemma or a detour;", "time": 880816}, {"__typename": "Cue", "text": "sometimes, even though\nwe may not know it at the time,", "time": 885753}, {"__typename": "Cue", "text": "the fork is the way home.", "time": 889087}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "Thank you very much.", "time": 891452}]}, {"__typename": "Paragraph", "cues": [{"__typename": "Cue", "text": "(Applause)", "time": 892802}]}]}, "video": {"__typename": "Video", "id": "46528", "talkExtras": {"__typename": "TalkExtras", "footnotes": [{"__typename": "Footnote", "author": null, "annotation": "> \"They've only worked in cancers caused by viruses, like cervical cancer or liver cancer. So cancer researchers basically gave up on the idea of using the immune system to fight cancer.\"\r\n\r\nA vaccine for hepatitis virus [can prevent](https://medlineplus.gov/ency/article/007613.htm) liver cancer and a vaccine for human papillomavirus [can prevent](https://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young-women.htm) cervical cancer. To date, the only [FDA-approved](https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-type-prostate-cancer-using-novel-clinical-trial-endpoint) vaccine treatment of cancer that is not caused by a virus is a dendritic cell vaccine for hormone-resistant metastatic prostate cancer termed Sipuleucel-T. However, the Sipuleucel-T vaccine has [limited efficacy](https://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1107698) and has been [controversial](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2730784) because the data supporting its efficacy is questionable. In a larger sense, researchers have [abandoned](https://www.ncbi.nlm.nih.gov/pubmed/15340416) standard vaccine approaches for cancer although there is a [resurgence](https://www.ncbi.nlm.nih.gov/pubmed/25837513) of interest in vaccines that target cancer-specific \u2018neoantigens\u2019.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "00:32", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"So we decided that the paradoxical thing that we had created with our B-cell antibodies, our T cells carrier and the HIV Trojan horse should be called \"Chimeric Antigen Receptor T cells,\" or CAR T cells.\"\r\n\r\nCAR T cells were [initially](https://www.ncbi.nlm.nih.gov/pubmed/8421711) called \u201cT bodies\u201d by Zelig Eshhar in 1993 and [later](https://www.ncbi.nlm.nih.gov/pubmed/11096442) renamed as \u201cchimeric antigen receptor T cells\" by Patrick Hwu and colleagues.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "02:37", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"And these designer cancer T cells, CAR T cells, have a calculated half-life of more than 17 years.\"\r\n\r\nThe number \"17\" was stated as rounding up from 16.5 years. In three separate clinical trials, the calculated half-life of the CAR T cells was between 16.5 and 24.5 years, as seen in [Table 1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368443/table/T1/?report=objectonly) of this paper.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "03:54", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"Then in 1997, we first tested CAR T cells in patients with advanced HIV-AIDS. And we found that those CAR T cells survived in the patients for more than a decade.\"\r\n\r\nThe [initial study](http://www.bloodjournal.org/content/bloodjournal/96/3/785.full.pdf?sso-checked=true) was published in 2000, and the [long-term follow-up study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368443/) was published in 2012.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "04:40", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"Just one CAR T cell can kill 1,000 tumor cells. That's right -- it's a ratio of one to 1,000.\"\r\n\r\nThe calculated effector CAR T cell to cancer target cell ratio was between 1:1000 and 1:93,000 in the first three patients treated with CTL019 CAR T cells, as shown in [Table S6](https://stm.sciencemag.org/content/scitransmed/suppl/2011/08/08/3.95.95ra73.DC1/3-95ra73_SM.pdf) of this paper.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "06:42", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"It was, in fact, more than a thousandfold above the normal levels.\"\r\n\r\nThe normal level of IL-6 in serum is [about](https://www.hindawi.com/journals/mi/2013/434010/) 10 pg/ml in children.  On day six after the CAR T cell infusion, the serum level of IL-6 in Emily was [790-fold](https://www.nejm.org/doi/10.1056/NEJMoa1215134?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov) above her pre-treatment level.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "08:52", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"We've found that it occurs in nearly all patients who respond to the therapy. But it does not happen in those patients who fail to respond. ... Unfortunately, not every patient recovers. Patients who do not get CRS are often those who are not cured.\"\r\n\r\nThe impression of investigators in the field is that patients with leukemia and lymphoma who do not experience CRS have an inferior clinical outcome.  However, this notion has not been rigorously tested and published.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "10:48", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"A remarkable study appeared in the\"New England Journal of Medicine\" in 2013. An international study has since confirmed those results.\"\r\n\r\nThe international study leading to FDA approval of tisagenlecleucel for acute leukemia was published in 2018 in this paper:\r\n\r\n[\"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.](https://www.researchgate.net/publication/322864245_Tisagenlecleucel_in_Children_and_Young_Adults_with_B-Cell_Lymphoblastic_Leukemia), Maude S.L., et al., *New England Journal of Medicine*.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "12:19", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"CAR T-cell therapy has also been tested now in adults with refractory lymphoma. This disease afflicts about 20,000 a year in the United States.\"\r\n\r\nLymphoma is the most common form of blood cancer in adults. There are [approximately](https://www.lls.org/facts-and-statistics/facts-and-statistics-overview/facts-and-statistics) 80,000 new cases of lymphoma diagnosed in the US every year. There are approximately [20,000](https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21551) deaths due to non-Hodgkin lymphoma per year in the US.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "12:43", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"Six months ago, the FDA approved the therapy of this advanced lymphoma with CAR T cells.\"\r\n\r\nThere are currently two FDA-approved CAR T cells for refractory lymphoma. The FDA approved [axicabtagene ciloleucel](https://www.fda.gov/news-events/press-announcements/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma) CAR T cells, marketed by Kite, in October 2017, and [tisagenlecleucel](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma) CAR T cells, marketed by Novartis, in May 2018.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "12:56", "title": null, "category": "note"}, {"__typename": "Footnote", "author": null, "annotation": "> \"It can cost up to 150,000 dollars to make the CAR T cells for each patient.\"\r\n\r\nThe cost to manufacture CAR T cells is approximately 100,000 dollars per patient and the current market price in the US for leukemia is approximately [475,000 dollars](https://khn.org/news/pioneering-cancer-gene-therapy-gets-greenlight-and-475000-price-tag/) and [373,000 dollars](https://www.ascopost.com/issues/may-25-2018/weighing-the-cost-and-value-of-car-t-cell-therapy/) for lymphoma. The marketed price for CAR T cells does not include costs for other ancillary medical costs such as infusion expenses. Issues of implementing a disruptive medical therapy surrounding CAR T cells have [recently](https://www.newyorker.com/magazine/2019/07/22/the-promise-and-price-of-cellular-therapies) been reviewed.", "date": null, "linkUrl": null, "source": null, "text": null, "timecode": "13:32", "title": null, "category": "note"}]}}}, "commentsEnabled": false, "commentsLoggedInOnly": false}, "language": "en", "messages": {}, "responseCode": 200, "__N_SSP": true}